<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="effective against CoVs, as are organic solvents such as ether," exact="alcohol" post="(60â€&quot;95%), chloroform, and disinfectants with a high concentration of"/>
 <result pre="in phase I of testing [11]. Four antiviral drugs, including" exact="hydroxychloroquine" post="(or chloroquine), favipiravir, lopinavir, and remdesivir, have entered phase"/>
 <result pre="and are briefly described below. Remdesivir Remdesivir (GS-5734) is an" exact="adenosine" post="analog drug that was produced for the treatment of"/>
 <result pre="CYP-3A4, indicating a possible interaction with related inhibitors such as" exact="ritonavir" post="and voriconazole. It has also been suggested that the"/>
 <result pre="efficacy on a wide scale in the fight against COVID-19." exact="Chloroquine" post="and hydroxychloroquine Chloroquine is an anti-parasitic drug that is"/>
 <result pre="a wide scale in the fight against COVID-19. Chloroquine and" exact="hydroxychloroquine" post="Chloroquine is an anti-parasitic drug that is used against"/>
 <result pre="wide scale in the fight against COVID-19. Chloroquine and hydroxychloroquine" exact="Chloroquine" post="is an anti-parasitic drug that is used against malaria"/>
 <result pre="potential use in treating COVID-19. The potential antiviral activity of" exact="chloroquine" post="against COVID-19 was first reported by Wang et al."/>
 <result pre="rationale for using this dosage remains vague. The use of" exact="chloroquine" post="has been associated with stability in patients, with better"/>
 <result pre="countries like the USA. As a substitute, another drug called" exact="hydroxychloroquine" post="is being investigated. It differs from chloroquine by the"/>
 <result pre="another drug called hydroxychloroquine is being investigated. It differs from" exact="chloroquine" post="by the presence of an additional hydroxyl group. It"/>
 <result pre="is assumed that this drug will be more effective than" exact="chloroquine" post="for treating COVID-19, the prolonged use of which has"/>
 <result pre="in rheumatic disorders. The current data regarding the activity of" exact="hydroxychloroquine" post="against CoVs are still inadequate. However, in 2006, a"/>
 <result pre="was examined by Biot et al. [91], who demonstrated that" exact="chloroquine" post="had superior antiviral activity against SARS-CoV-1 compared to hydroxychloroquine."/>
 <result pre="the findings were the opposite of the previous ones, with" exact="hydroxychloroquine" post="being more effective than chloroquine against SARS-CoV-2 when the"/>
 <result pre="of the previous ones, with hydroxychloroquine being more effective than" exact="chloroquine" post="against SARS-CoV-2 when the â€œratio of the free lung"/>
 <result pre="(RLTEC) values were compared [65]. The reported efficacious dosage of" exact="chloroquine" post="was more than 400Â mg, and therefore, the dosage"/>
 <result pre="was more than 400Â mg, and therefore, the dosage of" exact="hydroxychloroquine" post="was set accordingly in another study [61], which found"/>
 <result pre="following days. This dosage resulted in higher RLTEC values for" exact="hydroxychloroquine" post="than chloroquine. The second dosage gave similar results, suggesting"/>
 <result pre="dosage gave similar results, suggesting that a lower dosage of" exact="hydroxychloroquine" post="was also effective [65]. However, it is important to"/>
 <result pre="and analyzed from the PBPK data for a dosage of" exact="hydroxychloroquine" post="less than 1000Â mg and varying regimens, RLTEC values"/>
 <result pre="consecutive days, which would vary drastically from the dosage of" exact="chloroquine" post="taken two times every day with RLTEC values. The"/>
 <result pre="reported the effect of oral administration of 200Â mg of" exact="hydroxychloroquine" post="after the passage of eight hours in patients infected"/>
 <result pre="stronger reduction in the viral load than the use of" exact="hydroxychloroquine" post="alone. This finding, although significant, is not sufficient, as"/>
 <result pre="viral load was noteworthy. The study included 26 patients receiving" exact="hydroxychloroquine" post="therapy, six of which were excluded from the study"/>
 <result pre="indicate that caution is needed in the administration of both" exact="chloroquine" post="and hydroxychloroquine, initial studies conducted in China have been"/>
 <result pre="has been addressed [94]. In the meantime, the administration of" exact="hydroxychloroquine" post="needs to be approached with caution. Lopinavir/ritonavir Lopinavir is"/>
 <result pre="effectiveness of the drug. The reported course of action of" exact="lopinavir" post="is the inhibition of the protease enzyme of the"/>
 <result pre="drugs against SARS-CoV-1 during its outbreak, and the administration of" exact="lopinavir" post="and ribavirin was observed to block replication of the"/>
 <result pre="SARS-CoV-1 during its outbreak, and the administration of lopinavir and" exact="ribavirin" post="was observed to block replication of the virus after"/>
 <result pre="efficacy when used in combination [96]. The potent activity of" exact="lopinavir" post="against SARS-CoV-1 was also reported by de Wilde et"/>
 <result pre="in subjects who had contracted HIV [98]. The potency of" exact="lopinavir" post="in combination with ritonavir was compared to that of"/>
 <result pre="contracted HIV [98]. The potency of lopinavir in combination with" exact="ritonavir" post="was compared to that of interferon beta (INF-Î²) against"/>
 <result pre="symptoms in animals infected with MERS-CoV after combined therapy with" exact="lopinavir" post="and ritonavir [99]. At present, a controlled study of"/>
 <result pre="animals infected with MERS-CoV after combined therapy with lopinavir and" exact="ritonavir" post="[99]. At present, a controlled study of combined therapy"/>
 <result pre="Chu et al. [96], in which it was used with" exact="ribavirin" post="and corticosteroid drugs. The subjects undergoing lopinavir/ritonavir therapy were"/>
 <result pre="The subjects undergoing lopinavir/ritonavir therapy were compared with subjects receiving" exact="ribavirin" post="along with corticosteroids, after which a considerable decrease in"/>
 <result pre="should be considered that their activity compared to remdesivir and" exact="chloroquine" post="in the case of SARS-CoV-1 was below average, and"/>
 <result pre="and chest imaging, may consider glucocorticoid that is equivalent to" exact="methylprednisolone" post="1â€&quot;2Â mg/kg/day for 3â€&quot;5Â days or less. Note that"/>
 <result pre="Chinese Thoracic Society recommends a lower dose,â€‰â‰¤â€‰0.5â€&quot;1Â mg/kg per day" exact="methylprednisolone" post="forâ€‰â‰¤â€‰7Â days in select patients, after careful consideration of"/>
 <result pre="and benefits [125]. Pharmacological treatments in which risks outweigh benefits" exact="Ribavirin" post="with or without interferon Ribavirin was approved in the"/>
 <result pre="in which risks outweigh benefits Ribavirin with or without interferon" exact="Ribavirin" post="was approved in the 1980s for viral hemorrhagic fever,"/>
 <result pre="transcription by inhibiting the synthesis of RNA. The combination of" exact="ribavirin" post="with corticosteroids and/or interferon against SARS-CoV-1 did not show"/>
 <result pre="and cytopenia [129]. Despite these observations, the Chinese guidelines recommend" exact="ribavirin" post="500Â mg IV 2â€&quot;3 times daily in combination with"/>
 <result pre="lack of experimental trials, it is not safe to use" exact="ribavirin" post="at the moment for the treatment of COVID-19. Oseltamivir"/>
 <result pre="The same is true for other neuraminidase inhibitors such as" exact="zanamivir" post="and peramivir. Currently, the available data also do not"/>
 <result pre="registered yet Darunavir/cobicistat Anti-retroviral HIV-1 protease inhibitor Not registered yet" exact="Disulfiram" post="Thiuram derivative Blocks alcohol oxidation Not registered yet Eculizumab"/>
 <result pre="HIV-1 protease inhibitor Not registered yet Disulfiram Thiuram derivative Blocks" exact="alcohol" post="oxidation Not registered yet Eculizumab Humanized, monoclonal IgG antibody"/>
 <result pre="Griffithsin Anti-HIV microbicide Potent HIV entry inhibitor Not registered yet" exact="Nelfinavir" post="Anti-retroviral An HIV-1 protease inhibitor Not registered yet Niclosamide"/>
 <result pre="yet Nelfinavir Anti-retroviral An HIV-1 protease inhibitor Not registered yet" exact="Niclosamide" post="Anthelminthic Not registered yet REGN3048 Human monoclonal antibody Binds"/>
 <result pre="monoclonal antibody/ used against rheumatoid arthritis IL-6 receptor antagonist USA" exact="Sofosbuvir" post="Antiviral A nucleotide analog inhibitor of hepatitis C virus"/>
 <result pre="against COVID-19 at various levels of infection and disease progression" exact="Nitric oxide" post="therapy against COVID-19 Nitric oxide gas is a human-friendly"/>
 <result pre="of infection and disease progression Nitric oxide therapy against COVID-19" exact="Nitric oxide" post="gas is a human-friendly gas due to the following"/>
 <result pre="2002â€&quot;2003. Critically ill patients can be treated by giving them" exact="nitric oxide" post="gas, which not only improves lung function but also"/>
 <result pre="Apr 2020 59.Request for emergency use authorization for use of" exact="chloroquine" post="phosphate or hydroxychloroquine sulfate supplied from the Strategic National"/>
 <result pre="for emergency use authorization for use of chloroquine phosphate or" exact="hydroxychloroquine" post="sulfate supplied from the Strategic National Stockpile for Treatment"/>
 <result pre="2020 60.CortegianiAIngogliaGIppolitoMGiarratanoAEinavSA systematic review on the eicacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J Crit Care20205727928332173110 61.Gao J,"/>
 <result pre="Crit Care20205727928332173110 61.Gao J, Tian Z, Yang X (2020) Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus PneumoniaExpert Consens Chloroquine"/>
 <result pre="for Chloroquine in the Treatment of Novel Coronavirus PneumoniaExpert Consens" exact="Chloroquine" post="Phosphate Treat Novel Coronavirus Pneumonia [in Chinese]202020201010011939 63.Physicians work"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="to treat coronavirus disease 2019 (COVID-19)Drug Discov Ther2020141586032147628 78.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of ebola and emerging"/>
 <result pre="the United States. https://www.medrxiv.org/content/10.1101/2020.03.09.20032896v1.full.pdf. Retrieved 14 Mar 2020 90.ColsonPRolainJ-MLagierJ-CBrouquiPRaoultDChloroquine and" exact="hydroxychloroquine" post="as available weapons to fight COVID-19Int J Antimicrob Agents202055410593232145363"/>
 <result pre="92.TettSEClinical pharmacokinetics of slow-acting antirheumatic drugsClin Pharmacokinet19932553924077904547 93.GautretPLagierJ-CParolaPMeddebLMailheMDoudierBet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID19: results of an open-label"/>
 <result pre="an open-label non-randomized clinical trialInt J Antimicrob Agents202056110594932205204 94.TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476232147496 95.RatiaKPeganSTakayamaJSleemanKCoughlinMBalijiSChaudhuriRFuWPrabhakarBSJohnsonMEA noncovalent class of papain-like protease/deubiquitinase"/>
</results>
